MedTrace Logo

Talimogene Laherparepvec in Patients With Unresectable Pancreatic Cancer

NCT00402025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2016-04-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety of injections of talimogene laherparepvec into patients with pancreatic cancer that cannot be removed by surgery. The study will also test whether the injections are effective in treating the tumor.

Conditions

Interventions

BIOLOGICAL

Talimogene Laherparepvec

Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.

Sponsors & Collaborators

  • BioVex Limited

    lead INDUSTRY

Principal Investigators

  • Neil N Senzer, MD · Mary Crowley Medical Research Center

  • Robert Coffin, PhD · BioVex Limited

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402025 on ClinicalTrials.gov